THE STORY OF OphtiMed
Rx
A Vision for Better Eye Care
Our unique drug promises to be simple, safe, and highly efficacious, with the potential to prevent blindness in millions of individuals, reduce the costs associated with caring for dry AMD cases, and bring enormous benefits to patients worldwide. Join us on our mission to revolutionize eye care and improve the lives of those affected by dry AMD.
Roadmap to Clinical Trials
We are, currently, conducting comprehensive preclinical research and development studies, with plans to be ready for Phase I clinical trials by late 2025. Our drug, delivered via intravitreal injection, can be easily administered by eye doctors in clinics, eliminating the need for hospitalization.
Intellectual Proprietary
OphtiMed Rx holds a use patent for treating retinal degenerative diseases with our compound or functional derivatives, granted in the USA, EU, and Israel. Additionally, a new patent protecting a novel formulation for ocular administration is currently underway.
Our Origins
OphtiMed Rx was born out of a vision to revolutionize eye care. Conceived in November 2021, our company emerged from the groundbreaking research of Professor Ayala Pollack. Initially supported by the Israel Innovation Authority (IIA), Mor Research Applications, and private investment, the seeds of our innovation took root.
A Journey of Growth
Since our inception, OphtiMed Rx has flourished through a strategic combination of funding sources. We have received invaluable support from the IIA, private equity investment from GO Innovation Group, and a grant from the Women TechEU program. This diverse backing has propelled our growth and allowed us to transform cutting-edge research into tangible solutions.
Shaping the Future of Eye Care
With a strong foundation and a passionate team, we are poised to shape the future of eye care. Our commitment to innovation, combined with our strategic partnerships and funding sources, ensures that we can continue to push boundaries and deliver groundbreaking products and services to patients worldwide.
MANAGEMENT TEAM
We've assembled a world-class team dedicated to advancing AMD research.
With the support of our esteemed advisory board, we're leveraging top talent to drive and expedite the R&D activities.
Co-Founder & CEO
A scientist, MedTech executive, and entrepreneur, has played a central role in driving OphtiMedRx's establishment. As the company's CEO, she leads with visionary and strategic leadership, contributing to R&D, business development, collaborations, and attracting investments.
Michal Aharoni-Simon, PhD
Head of R&D
With over two decades of experience in pre-clinical research, brings invaluable expertise to OphtiMedRx. Her leadership, recognized with awards and patents, is integral to the company's vision for advancing ophthalmology and developing innovative retinal degeneration solutions.
SCIENTIFIC ADVISORY BOARD
A professor of Ophthalmology affiliated with the Hebrew University Hadassah Medical School and entrepreneur, played a pivotal role in OphtiMedRx's technology.
As the former Head of the Ophthalmology Department at Kaplan Medical Center, she led pioneering research into retinal diseases. With multiple patents in retinal degeneration treatment, her expertise guides OphtiMedRx as its direct Medical Advisor.
A luminary in retinal health, directs the Ophthalmology Department at Tel-Aviv Medical Center and holds prestigious positions at Tel Aviv University. Globally recognized for innovative contributions, she plays a key role in supporting development of groundbreaking technologies.
World-known retina specialist. Chief of the Retina Service at the UCI Gavin Herbert Eye Institute. Has extensive research collaborations with biotechnology companies and serves as an advisor to bring new treatments to patients for retinal diseases.
BOARD OF DIRECTORS
Co-Chairman of the BoD, Former executive BD roles in Lilly, Abbott, Becton Dickinson, Allergan/Abbvie, and Santen
